CN102066444A - 胶束装配体 - Google Patents

胶束装配体 Download PDF

Info

Publication number
CN102066444A
CN102066444A CN2009801234403A CN200980123440A CN102066444A CN 102066444 A CN102066444 A CN 102066444A CN 2009801234403 A CN2009801234403 A CN 2009801234403A CN 200980123440 A CN200980123440 A CN 200980123440A CN 102066444 A CN102066444 A CN 102066444A
Authority
CN
China
Prior art keywords
micellic assembly
block
micellic
chargeable
species
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801234403A
Other languages
English (en)
Chinese (zh)
Inventor
P·S·司泰同
A·S·霍夫曼
A·J·肯沃汀
C·L·杜瓦尔
D·本诺特
R·欧沃瑞尔
P·约翰逊
A·高尔
M·普里福
A·帕沙尔
C·迪亚布
P·德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
PhaseRx Inc
Original Assignee
University of Washington
PhaseRx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, PhaseRx Inc filed Critical University of Washington
Publication of CN102066444A publication Critical patent/CN102066444A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F290/00—Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups
    • C08F290/02—Macromolecular compounds obtained by polymerising monomers on to polymers modified by introduction of aliphatic unsaturated end or side groups on to polymers modified by introduction of unsaturated end groups
    • C08F290/06—Polymers provided for in subclass C08G
    • C08F290/062—Polyethers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
    • C08F293/005—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule using free radical "living" or "controlled" polymerisation, e.g. using a complexing agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Polymers & Plastics (AREA)
  • Dispersion Chemistry (AREA)
  • Obesity (AREA)
  • Nanotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
CN2009801234403A 2008-05-13 2009-05-13 胶束装配体 Pending CN102066444A (zh)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US5291408P 2008-05-13 2008-05-13
US5290808P 2008-05-13 2008-05-13
US61/052,908 2008-05-13
US61/052,914 2008-05-13
US9129408P 2008-08-22 2008-08-22
US61/091,294 2008-08-22
US11204808P 2008-11-06 2008-11-06
US61/112,048 2008-11-06
US14077408P 2008-12-24 2008-12-24
US61/140,774 2008-12-24
US17136909P 2009-04-21 2009-04-21
US61/171,369 2009-04-21
PCT/US2009/043849 WO2009140429A2 (en) 2008-05-13 2009-05-13 Micellic assemblies

Publications (1)

Publication Number Publication Date
CN102066444A true CN102066444A (zh) 2011-05-18

Family

ID=41319324

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801234403A Pending CN102066444A (zh) 2008-05-13 2009-05-13 胶束装配体

Country Status (13)

Country Link
US (4) US9339558B2 (https=)
EP (1) EP2285853B1 (https=)
JP (2) JP5755563B2 (https=)
KR (1) KR101764427B1 (https=)
CN (1) CN102066444A (https=)
AU (1) AU2009246329B8 (https=)
BR (1) BRPI0911989A2 (https=)
CA (1) CA2724014C (https=)
ES (1) ES2404136T3 (https=)
IL (1) IL209239A0 (https=)
MX (1) MX2010012239A (https=)
WO (1) WO2009140429A2 (https=)
ZA (1) ZA201008730B (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107530436A (zh) * 2015-01-21 2018-01-02 菲泽尔克斯公司 用于将治疗剂和诊断剂递送到细胞中的方法、组合物和系统
CN108392471A (zh) * 2018-03-01 2018-08-14 苏州大学张家港工业技术研究院 基于末端含硫辛酰基星型聚合物的纳米药物
CN110730656A (zh) * 2017-06-02 2020-01-24 特一华制药株式会社 水难溶性成分增溶胶束及含有该胶束的液体制剂
CN112279983A (zh) * 2020-10-30 2021-01-29 金陵科技学院 一种电荷翻转两亲嵌段共聚物、制备方法、前体聚合物、纳米胶束和应用
CN114555654A (zh) * 2019-09-13 2022-05-27 波音公司 抗微生物纳米蠕虫
CN115803353A (zh) * 2020-04-30 2023-03-14 陶氏环球技术有限责任公司 通过raft聚合制备烯烃-丙烯酸酯嵌段共聚物的方法

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7981688B2 (en) 2007-03-08 2011-07-19 University Of Washington Stimuli-responsive magnetic nanoparticles and related methods
US8034396B2 (en) 2008-04-01 2011-10-11 Tyco Healthcare Group Lp Bioadhesive composition formed using click chemistry
KR101764427B1 (ko) 2008-05-13 2017-08-02 유니버시티 오브 워싱톤 미셀성 어셈블리
WO2009140421A2 (en) * 2008-05-13 2009-11-19 University Of Washington Polymeric carrier
CN103342789B (zh) * 2008-05-13 2016-11-23 华盛顿大学 用于向细胞内递送的二嵌段共聚物和其多核苷酸复合物
WO2010021770A1 (en) 2008-08-22 2010-02-25 University Of Washington Heterogeneous polymeric micelles for intracellular delivery
EP2364330B1 (en) * 2008-11-06 2015-03-25 University Of Washington Multiblock copolymers
EP2352522A4 (en) 2008-11-06 2014-03-05 Univ Washington BISPECIFIC AUXILIARIES FOR INTRA-CELLULAR RELEASE
US9593169B2 (en) 2008-12-08 2017-03-14 University Of Washington Omega-functionalized polymers, junction-functionalized block copolymers, polymer bioconjugates, and radical chain extension polymerization
US8535477B2 (en) 2009-02-21 2013-09-17 Sofradim Production Medical devices incorporating functional adhesives
US8877170B2 (en) 2009-02-21 2014-11-04 Sofradim Production Medical device with inflammatory response-reducing coating
US8663689B2 (en) 2009-02-21 2014-03-04 Sofradim Production Functionalized adhesive medical gel
US8512728B2 (en) 2009-02-21 2013-08-20 Sofradim Production Method of forming a medical device on biological tissue
US8968733B2 (en) 2009-02-21 2015-03-03 Sofradim Production Functionalized surgical adhesives
US8426214B2 (en) 2009-06-12 2013-04-23 University Of Washington System and method for magnetically concentrating and detecting biomarkers
US9080933B2 (en) 2009-11-09 2015-07-14 University Of Washington Through Its Center For Commercialization Stimuli-responsive polymer diagnostic assay comprising magnetic nanoparticles and capture conjugates
WO2011060281A1 (en) * 2009-11-13 2011-05-19 University Of Washington Through Its Center For Commercialization Hydrophobic block conjugated therapeutic agents
WO2011062965A2 (en) 2009-11-18 2011-05-26 University Of Washington Through Its Center For Commercialization Targeting monomers and polymers having targeting blocks
US8349308B2 (en) 2010-03-26 2013-01-08 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
CA2804263A1 (en) 2010-06-29 2012-01-12 Tyco Healthcare Group Lp Microwave-powered reactor and method for in situ forming implants
EP2588153A2 (en) 2010-07-01 2013-05-08 Sofradim Production Medical device with predefined activated cellular integration
EP3345944B1 (en) 2010-09-22 2020-03-18 The Board of Regents of the University of Texas System Novel block copolymer and micelle compositions and methods of use thereof
CA2859127C (en) * 2011-12-15 2017-04-25 Bioneer Corporation Novel oligonucleotide conjugates and use thereof
JP6195848B2 (ja) * 2012-01-27 2017-09-13 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ 糖ポリマーを用いた生体分子の安定化
US9808480B2 (en) 2012-04-27 2017-11-07 Nanocarrier Co., Ltd. Unit structure-type pharmaceutical composition for nucleic acid delivery
WO2014015367A1 (en) * 2012-07-23 2014-01-30 The University Of Queensland Polymers for sirna delivery
US10046086B2 (en) 2012-09-21 2018-08-14 Vanderbilt University Poly(thioketal-urethane) scaffolds and methods of use
WO2014047524A1 (en) 2012-09-21 2014-03-27 Vanderbilt University Poly(thioketal-urethane) scaffolds and methods of use
US10172956B2 (en) * 2012-10-26 2019-01-08 Vanderbilt University Polymeric nanoparticles
CN105142620B (zh) 2013-02-25 2018-09-28 罗切斯特大学 用于受控释放抗生物膜剂的纳米颗粒
CN103319661B (zh) * 2013-05-24 2015-05-20 天津大学 琼脂糖基硫代甜菜碱丙烯酸酯接枝聚合物及其制备方法
US9775928B2 (en) 2013-06-18 2017-10-03 Covidien Lp Adhesive barbed filament
EP3027221A1 (en) 2013-07-30 2016-06-08 PhaseRx, Inc. Block copolymers and their conjugates or complexes with oligonucleotides
ES2777302T3 (es) * 2014-03-27 2020-08-04 Sika Tech Ag Copolímero de bloque
US10695288B2 (en) 2014-11-19 2020-06-30 Vanderbilt University Reactive oxygen species (ROS)-responsive compositions and methods thereof
US20210330599A1 (en) 2016-08-01 2021-10-28 University Of Rochester Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use
JP7387429B2 (ja) * 2016-08-26 2023-11-28 キレーション パートナーズ インコーポレイテッド 生細胞および生物の増殖および活性を制御するためのポリマー性金属キレート組成物およびその調製方法
KR102350647B1 (ko) 2016-09-02 2022-01-14 다이서나 파마수이티컬, 인크. 4'-포스페이트 유사체 및 이를 포함하는 올리고뉴클레오타이드
WO2018067648A1 (en) * 2016-10-04 2018-04-12 Cornell University Lubricating block copolymers and their use as biomimetic boundary lubricants
JP6912876B2 (ja) * 2016-10-06 2021-08-04 三洋化成工業株式会社 アクリル系医薬固形製剤用添加剤
EP3533524A4 (en) * 2016-10-28 2020-07-15 Oji Holdings Corporation PATTERN FORMING METHOD, BASE AGENT AND LAMINATE
WO2018126084A1 (en) 2016-12-30 2018-07-05 Phaserx, Inc. Branched peg molecules and related compositions and methods
EP3677268A4 (en) 2017-08-31 2021-04-21 The University Of Tokyo UNIFORM POLYIONAL COMPLEX LOADED WITH NUCLEIC ACID
KR20210120988A (ko) * 2018-11-02 2021-10-07 제네반트 사이언시즈 게엠베하 치료 방법
CN109528648A (zh) * 2018-12-11 2019-03-29 中国药科大学 肿瘤基质微酸环境响应的两亲性高分子前药胶束及其制备方法和应用
WO2020205473A1 (en) 2019-03-29 2020-10-08 Decerna Pharmaceuticals, Inc. Compositions and methods for the treatment of kras associated diseases or disorders
WO2020226960A1 (en) 2019-05-03 2020-11-12 Dicerna Pharmaceuticals, Inc. Double-stranded nucleic acid inhibitor molecules with shortened sense strands
US20220226239A1 (en) * 2019-06-04 2022-07-21 Aravasc Inc. Polymeric micelle complexes, formulations, and uses thereof
JP2021046542A (ja) * 2019-09-10 2021-03-25 独立行政法人国立高等専門学校機構 両親媒性ブロック共重合体
BR112022013821A2 (pt) 2020-01-15 2022-09-13 Dicerna Pharmaceuticals Inc Ácidos nucleicos de 4?-o-metileno fosfonato e seus análogos
US11786464B2 (en) 2020-04-24 2023-10-17 The Board Of Regents Of The University Of Texas System PH responsive block copolymer compositions and micelles that inhibit MCT 1 and related proteins
WO2022010764A1 (en) * 2020-07-06 2022-01-13 Vivtex Corporation Mucopenetrating formulations
IL300283A (en) 2020-08-04 2023-04-01 Dicerna Pharmaceuticals Inc Systemic administration of oligonucleotides
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
WO2025038596A1 (en) * 2023-08-15 2025-02-20 University Of Washington De novo genetically-encodable polypeptides for extracellular protein degradation, and fusion proteins thereof
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US4877603A (en) 1987-12-18 1989-10-31 The Procter & Gamble Company Oral compositions
US5219945A (en) * 1992-02-20 1993-06-15 E. I. Du Pont De Nemours And Company ABC triblock methacrylate polymers
US6359054B1 (en) 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
WO1997049387A1 (en) * 1996-06-27 1997-12-31 G.D. Searle And Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
FR2767829B1 (fr) 1997-09-01 1999-12-03 Georges Sturtz Composes phosphonates ou gem-bisphosphonates acryliques ou methacryliques
US6210717B1 (en) 1997-12-12 2001-04-03 Samyang Corporation Biodegradable mixed polymeric micelles for gene delivery
US6410057B1 (en) 1997-12-12 2002-06-25 Samyang Corporation Biodegradable mixed polymeric micelles for drug delivery
US6383811B2 (en) 1997-12-30 2002-05-07 Mirus Corporation Polyampholytes for delivering polyions to a cell
ATE443528T1 (de) 1998-01-05 2009-10-15 Univ Washington Erhöhter transport unter benutzung membranzerstörender stoffe
DE10220470A1 (de) * 2002-04-30 2003-11-20 Roehm Gmbh ph-sensitives Polymer
US6306994B1 (en) 1999-05-14 2001-10-23 E. I. Du Pont De Nemours And Company Inks with enhanced substrate binding characteristics
US8137695B2 (en) 2006-08-18 2012-03-20 Arrowhead Madison Inc. Polyconjugates for in vivo delivery of polynucleotides
US7098032B2 (en) 2001-01-02 2006-08-29 Mirus Bio Corporation Compositions and methods for drug delivery using pH sensitive molecules
US6916488B1 (en) * 1999-11-05 2005-07-12 Biocure, Inc. Amphiphilic polymeric vesicles
US7033607B2 (en) 1999-12-31 2006-04-25 Mirus Bio Corporation pH-titratable polyampholytes for delivering polyions to a cell
US7737108B1 (en) 2000-01-07 2010-06-15 University Of Washington Enhanced transport using membrane disruptive agents
US20030134420A1 (en) 2000-02-18 2003-07-17 Lollo Charles Peter Methods and compositions for gene delivery
EP1286643A2 (en) 2000-05-17 2003-03-05 Labopharm Inc. Drug containing polymeric micelles
SE517421C2 (sv) 2000-10-06 2002-06-04 Bioglan Ab Mikropartiklar, lämpade för parenteral administration, väsentligen bestående av stärkelse med minst 85 % amylopektin och med reducerad molekylvikt, samt framställning därav
WO2003087188A1 (en) 2001-04-26 2003-10-23 Nanosphere, Inc. Oligonucleotide-modified romp polymers and co-polymers
US7094810B2 (en) 2001-06-08 2006-08-22 Labopharm, Inc. pH-sensitive block copolymers for pharmaceutical compositions
US6939564B2 (en) 2001-06-08 2005-09-06 Labopharm, Inc. Water-soluble stabilized self-assembled polyelectrolytes
US6780428B2 (en) 2001-06-08 2004-08-24 Labopharm, Inc. Unimolecular polymeric micelles with an ionizable inner core
KR100566911B1 (ko) * 2001-06-25 2006-04-03 주식회사 삼양사 약물 전달체용 음이온기-함유 양친성 블록 공중합체 및 그의 양이온성 약물과의 복합체
US6906128B2 (en) * 2001-12-12 2005-06-14 Rhodia Chimie Method for depositing a polymer onto a surface by applying a composition onto said surface
US20030191081A1 (en) 2001-12-28 2003-10-09 Pierre Lemieux Pharmaceutical compositions and methods of use thereof comprising polyanionic polymers and amphiphilic block copolymers to improve gene expression
JP3936966B2 (ja) * 2002-02-28 2007-06-27 サンノプコ株式会社 顔料塗被紙用塗料用コバインダーおよび顔料塗被紙
US20050220880A1 (en) 2002-03-07 2005-10-06 Lewis Andrew L Drug carriers comprising amphiphilic block copolymers
US7229973B2 (en) 2002-05-19 2007-06-12 You Han Bae pH-sensitive polymeric micelles for drug delivery
EP1400555A1 (en) 2002-09-17 2004-03-24 Kawamura Institute Of Chemical Research Water-soluble block copolymer and production method therefor
JP2006505686A (ja) * 2002-11-07 2006-02-16 ロディア・シミ 両性又は双極性イオン性部分を含む制御された構造のコポリマー
AU2003293082A1 (en) 2002-11-27 2004-06-23 Tufts University Antioxidant-functionalized polymers
ATE461961T1 (de) 2002-12-30 2010-04-15 Nektar Therapeutics Mehrarmige polypeptid-poly(ethylenglykol)- blockcopolymere als arzneistoffzufuhrvehikel
US7871818B2 (en) 2003-01-31 2011-01-18 Roche Madison Inc. Membrane active polymers
US7217776B1 (en) 2003-02-14 2007-05-15 Iowa State University Research Foundation pH-sensitive methacrylic copolymer gels and the production thereof
US20040162235A1 (en) 2003-02-18 2004-08-19 Trubetskoy Vladimir S. Delivery of siRNA to cells using polyampholytes
JP4535229B2 (ja) 2003-05-08 2010-09-01 国立大学法人 東京大学 ポリエチレングリコール−ポリカチオンブロック共重合体
EP1660548B1 (en) * 2003-09-03 2008-08-27 Rhodia Inc. New copolymer having a controlled structure, and use thereof
US7632905B2 (en) 2004-04-09 2009-12-15 L'oreal S.A. Block copolymer, composition comprising it and cosmetic treatment process
US20080274454A1 (en) 2004-04-07 2008-11-06 Mirkin Chad A Reversible and Chemically Programmable Micelle Assembly With Dna Block-Copolymer Amphiphiles
US8821859B2 (en) 2004-05-19 2014-09-02 Agency For Science, Technology And Research Methods and articles for the delivery of therapeutic agents
GB0418123D0 (en) * 2004-08-13 2004-09-15 Asahi Chemical Ind Polymers useful as medical materials
US20060134221A1 (en) 2004-12-03 2006-06-22 Vical Incorporated Methods for producing block copolymer/amphiphilic particles
US20060165810A1 (en) 2004-12-28 2006-07-27 The Trustees Of The University Of Pennsylvania Controlled release from block co-polymer worm micelles
US20060171980A1 (en) 2005-02-01 2006-08-03 Helmus Michael N Implantable or insertable medical devices having optimal surface energy
EP1863859A4 (en) 2005-03-31 2009-04-22 Ap Pharma Inc PEG-POLYACETAL AND PEG-POLYACETAL-POE-PFROPOPOPOLYMERS AND PHARMACEUTICAL COMPOSITIONS
EP1868664A2 (en) 2005-04-15 2007-12-26 Interface Biologics Inc. Methods and compositions for the delivery of biologically active agents
US9139850B2 (en) 2005-05-19 2015-09-22 L'oreal Vectorization of dsRNA by cationic particles and topical use
EP1891141B1 (en) 2005-05-31 2016-11-16 Ecole Polytechnique Fédérale de Lausanne (EPFL) Triblock copolymers for cytoplasmic delivery of gene-based drugs
FR2890859B1 (fr) 2005-09-21 2012-12-21 Oreal Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase
WO2007109584A1 (en) 2006-03-16 2007-09-27 University Of Washington Temperature-and ph-responsive polymer compositions
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
CN101501108A (zh) * 2006-07-05 2009-08-05 新加坡科技研究局 用于药物递送的胶束
JP2008050506A (ja) * 2006-08-25 2008-03-06 Canon Inc 組成物
WO2008085556A2 (en) 2006-09-12 2008-07-17 University Of South Florida Surfactant-free nanoparticles for drug delivery
US20080081075A1 (en) 2006-10-02 2008-04-03 National Tsing Hua University Multifunctional mixed micelle of graft and block copolymers and preparation thereof
GB0624729D0 (en) * 2006-12-12 2007-01-17 Univ Leeds Reversible micelles and applications for their use
WO2008071009A1 (en) 2006-12-15 2008-06-19 The Governors Of The University Of Alberta Novel ligand guided block copolymers for targeted drug delivery
WO2008088658A2 (en) 2007-01-17 2008-07-24 Immunomedics, Inc. Polymeric carriers of therapeutic agents and recognition moieties for antibody-based targeting of disease sites
US20080311045A1 (en) 2007-06-06 2008-12-18 Biovaluation & Analysis, Inc. Polymersomes for Use in Acoustically Mediated Intracellular Drug Delivery in vivo
WO2008148174A1 (en) 2007-06-08 2008-12-11 Queensland University Of Technology Wound repair composition and method
WO2008153940A1 (en) 2007-06-11 2008-12-18 Biocure, Inc. Vesicles for active macromolecule delivery
JP2010532786A (ja) 2007-07-06 2010-10-14 ノースイースタン ユニバーシティ Ｒｎａ薬剤の両親媒性接合を含む混合ミセルおよびその使用
US20090036625A1 (en) 2007-08-01 2009-02-05 Chung Yuan Christian University Amphiphilic Polymer, Method for Forming the Same and Application thereof
EP2025348A1 (en) 2007-08-13 2009-02-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Targeted block copolymer micelles
US20110142951A1 (en) 2008-05-13 2011-06-16 University Of Washington Micelles for intracellular delivery of therapeutic agents
KR101764427B1 (ko) 2008-05-13 2017-08-02 유니버시티 오브 워싱톤 미셀성 어셈블리
WO2009140421A2 (en) 2008-05-13 2009-11-19 University Of Washington Polymeric carrier
US20110129921A1 (en) 2008-05-13 2011-06-02 University Of Washington Targeted polymer bioconjugates
CN103342789B (zh) 2008-05-13 2016-11-23 华盛顿大学 用于向细胞内递送的二嵌段共聚物和其多核苷酸复合物
WO2010021770A1 (en) 2008-08-22 2010-02-25 University Of Washington Heterogeneous polymeric micelles for intracellular delivery
ES2366758T3 (es) 2008-10-22 2011-10-25 Clariant Finance (Bvi) Limited Compuestos de fosfonato olefínicamente insaturados, polímeros fabricados a partir de ellos, y su uso.
EP2364330B1 (en) 2008-11-06 2015-03-25 University Of Washington Multiblock copolymers
US20110281934A1 (en) 2008-11-06 2011-11-17 Phaserx, Inc. Micelles of hydrophilically shielded membrane-destabilizing copolymers
EP2352522A4 (en) 2008-11-06 2014-03-05 Univ Washington BISPECIFIC AUXILIARIES FOR INTRA-CELLULAR RELEASE
US20100150952A1 (en) 2008-11-07 2010-06-17 University Of Washington pH-RESPONSIVE POLYMER CARRIER COMPOSITIONS FOR CYTOSOLIC PROTEIN DELIVERY
US9593169B2 (en) 2008-12-08 2017-03-14 University Of Washington Omega-functionalized polymers, junction-functionalized block copolymers, polymer bioconjugates, and radical chain extension polymerization

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107530436A (zh) * 2015-01-21 2018-01-02 菲泽尔克斯公司 用于将治疗剂和诊断剂递送到细胞中的方法、组合物和系统
CN110730656A (zh) * 2017-06-02 2020-01-24 特一华制药株式会社 水难溶性成分增溶胶束及含有该胶束的液体制剂
CN110730656B (zh) * 2017-06-02 2022-09-16 特一华制药株式会社 水难溶性成分增溶胶束及含有该胶束的液体制剂
CN108392471A (zh) * 2018-03-01 2018-08-14 苏州大学张家港工业技术研究院 基于末端含硫辛酰基星型聚合物的纳米药物
CN114555654A (zh) * 2019-09-13 2022-05-27 波音公司 抗微生物纳米蠕虫
CN114555654B (zh) * 2019-09-13 2024-03-15 波音公司 抗微生物纳米蠕虫
CN115803353A (zh) * 2020-04-30 2023-03-14 陶氏环球技术有限责任公司 通过raft聚合制备烯烃-丙烯酸酯嵌段共聚物的方法
CN112279983A (zh) * 2020-10-30 2021-01-29 金陵科技学院 一种电荷翻转两亲嵌段共聚物、制备方法、前体聚合物、纳米胶束和应用
CN112279983B (zh) * 2020-10-30 2022-12-20 金陵科技学院 一种电荷翻转两亲嵌段共聚物、制备方法、前体聚合物、纳米胶束和应用

Also Published As

Publication number Publication date
WO2009140429A2 (en) 2009-11-19
US9339558B2 (en) 2016-05-17
JP2015221898A (ja) 2015-12-10
KR20110020803A (ko) 2011-03-03
CA2724014A1 (en) 2009-11-19
US10420790B2 (en) 2019-09-24
US20110123636A1 (en) 2011-05-26
US20170239360A1 (en) 2017-08-24
US20160250338A1 (en) 2016-09-01
IL209239A0 (en) 2011-01-31
US9662403B2 (en) 2017-05-30
BRPI0911989A2 (pt) 2015-10-20
ZA201008730B (en) 2012-05-30
US20200147121A1 (en) 2020-05-14
EP2285853B1 (en) 2013-02-27
AU2009246329A1 (en) 2009-11-19
AU2009246329A8 (en) 2011-01-20
CA2724014C (en) 2016-09-13
JP2011522070A (ja) 2011-07-28
AU2009246329B2 (en) 2013-11-07
WO2009140429A3 (en) 2010-02-25
KR101764427B1 (ko) 2017-08-02
US11707483B2 (en) 2023-07-25
EP2285853A2 (en) 2011-02-23
EP2285853A4 (en) 2011-10-26
AU2009246329B8 (en) 2013-12-05
JP5755563B2 (ja) 2015-07-29
ES2404136T3 (es) 2013-05-24
MX2010012239A (es) 2011-05-24

Similar Documents

Publication Publication Date Title
US11707483B2 (en) Micellic assemblies
US9006193B2 (en) Polymeric carrier
EP2364330B1 (en) Multiblock copolymers
US9415113B2 (en) Targeting monomers and polymers having targeting blocks
CN102076328A (zh) 用于胞内递送治疗剂的胶束
US20130017167A1 (en) Hydrophobic block conjugated therapeutic agents

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110518